37 results about "Mycoplasma hyopneumoniae Antigen" patented technology

The present invention provides a Mycoplasma hyopneumoniae strain HN0613 strain which is isolated and identified as having better immunogenicity, and also provides the Mycoplasma hyopneumoniae antigen prepared by the above-mentioned Mycoplasma hyopneumoniae HN0613 strain and the Mycoplasma hyopneumoniae pneumonia vaccine containing the Mycoplasma hyopneumoniae antigen . The present invention also provides a dual combination vaccine of porcine circovirus type 2 and mycoplasma hyopneumoniae, comprising PCV2 antigen (inactivated porcine circovirus type 2 antigen or PCV2 ORF2 protein), inactivated mycoplasma hyopneumoniae and vaccine adjuvant agent. The combination vaccine of the present invention can prevent porcine circovirus disease and swine mycoplasma pneumonia with one shot of the vaccine, and has a preventive and protective effect on mycoplasma hyopneumoniae infection.

The invention provides a fusion protein and a composition and application of the mycoplasma pneumonia vaccine containing the fusion protein. The fusion protein includes Pseudomonas aeruginosa exotoxin A domain I and II, Mycoplasma hyopneumoniae antigenic protein and carboxyl terminal part, and the Mycoplasma hyopneumoniae antigenic protein includes NrdF protein, P102 protein, P97R1 protein, P97R2 protein, P97R1 protein Any protein in -NrdF protein, P97R2-NrdF protein. The invention also discloses a vaccine composition containing immune amount fusion protein and its application in the preparation of medicine for preventing and / or treating swine mycoplasma pneumonia. The vaccine composition can carry out a large amount of recombinant expression on the components of the vaccine composition by means of genetic engineering, which not only takes a short time, but also facilitates large-scale production; the vaccine composition can produce both humoral immunity and cellular immunity , can obtain a better immune effect.

The invention belongs to the technical field of veterinary biological products, in particular to a dual inactivated vaccine of Mycoplasma hyopneumoniae and Haemophilus parasuis serotypes 2, 5 and 7. The vaccine is made of Mycoplasma hyopneumoniae antigen, three Haemophilus parasuis serotype antigens and immune adjuvants, wherein the Mycoplasma hyopneumoniae antigen is the inactivated Mycoplasma hyopneumoniae HNMhy1 strain antigen, and the Mycoplasma hyopneumoniae HNMhy1 strain , the preservation number is CGMCC NO: 13858, and the preservation date is May 26, 2017; the three serotype antigens of Haemophilus parasuis are respectively inactivated Haemophilus parasuis type 2 HN1553 strain and type 5 HN1570 strain and type 7 HN1565 strain antigen, wherein the Haemophilus parasuis type 2 HN1553 strain has a preservation number of CGMCC NO: 16801; the Haemophilus parasuis serotype 5 HN1570 strain has a preservation number of CGMCC NO: 16802; The Haemophilus parasuis serotype 7 HN1565 strain has a preservation number of CGMCC NO: 16803; the immune adjuvant is aluminum hydroxide gel adjuvant.

The invention provides a vaccine composition, which comprises porcine circovirus antigen of immune amount, mycoplasma hyopneumoniae antigen of immune amount, and levamisole or its derivatives and polymers. The vaccine composition not only can simultaneously play an immune enhancing effect on two antigens, but also has stability, and can be used for diluting porcine reproduction and respiratory syndrome live vaccine.

The present invention provides a vaccine composition comprising an immune amount of Mycoplasma hyopneumoniae antigen, an immune amount of a Haemophilus parasuis antigen, and an immune amount of an antigen of Porcine Reproductive and Respiratory Syndrome Virus. The vaccine composition is infected with porcine reproductive and respiratory syndrome virus, Mycoplasma hyopneumoniae and Haemophilus parasuis on the 14th day after the second immunization, and can protect more than 80% of pigs without mutual interference between antigens, and achieves impressive results. Satisfactory immune effect.

The present invention provides a vaccine adjuvant composition for treatment or prevention of swine infectious diseases. The vaccine adjuvant composition contains a milkvetch root extract, a polymer and an antigen component, or contains a milkvetch root extract, a polymer, cyclodextrin and an antigen component. The vaccine adjuvant can be combined with porcine circovirus antigen or mycoplasma hyopneumoniae antigen so as to substantially improve vaccine immune efficacy, wherein the original immune efficacy can be achieved after reducing the amount of the vaccine to the half of the amount of the original antigen; and test results of the vaccine adjuvant with a plurality of doses show that: the vaccine adjuvant does not have a significant side effect, and provides significantly reduced side effect compared with the commonly used oil phase adjuvant.